Catalyst Dossier · compiled by CeliA 🧫

Sanofi (SNYNF)

Biotechnology · market cap $99.8B · as of 2026-07-08

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-08-15 (est.)

Phase 3

Pipeline

programs

Upcoming events

next 90d+

Dossier

Ready

cached

Non-US-listed company. Financial statements and forensic scores here come from US SEC filings (10-K/10-Q), which foreign issuers don’t file — those sections may be blank. The catalyst calendar, pipeline, approval odds, price context and (where covered) analyst targets still apply.

Sanofi (SNYNF) is a large-cap global biopharmaceutical company with approximately 74,846 employees and a market capitalization of ~$99.8B. The company carries a broad, diversified pipeline spanning Phase 2–3 across immunology, rare diseases, vaccines, oncology, and cardiometabolic indications. Near-term catalysts are concentrated in fitusiran (Phase 3, imp 9/10, August 2026) and PCV21 (Phase 3, imp 9/10, January 2027), alongside several Phase 2 readouts.

The catalyst path

2026-08-15 (est.)Phase 3 · Fitusiranimp 9/10
2026-10-30 (est.)Phase 2 · venglustat (GZ402671)imp 7/10
2026-12-23 (est.)Phase 2 · frexalimabimp 7/10
2027-01-07 (est.)Phase 3 · PCV21imp 9/10

Pipeline

Asset	Phase	Indication
Teriflunomide (HMR1726)	Phase 3	Multiple Sclerosis
DTaP-IPV-HB-PRP~T vaccine	Phase 3	Diphtheria
SAR3419	Phase 2	Diffuse Large B-cell Lymphoma
XRP0038 (NV1FGF)	Phase 2	Peripheral Arterial Occlusive Disease
Insulin glargine/lixisenatide Fixed Ratio Combination	Phase 3	Type 2 Diabetes
Irbesartan	Phase 3	Atrial Fibrillation
Split, Inactivated, Trivalent Influenza Vaccine	Phase 2	Orthomyxoviridae Infection
Human Anti-Transforming Growth Factor Beta-1 Monoclonal Antibody	Phase 2	Systemic Sclerosis
Levofolinate	Phase 2	Colorectal Cancer Metastatic
teriflunomide HMR1726	Phase 3	Multiple Sclerosis
Mitoxantrone	Phase 3	Prostatic Neoplasms
rhIDU (recombinant human-Alpha-L-Iduronidase)	Phase 3	Mucopolysaccharidosis I
escitalopram	Phase 3	Major Depressive Disorder
SR121463B	Phase 3	Inappropriate ADH Syndrome
Olipudase alfa	Phase 3	Sphingomyelin Lipidosis
Myozyme	Phase 3	Glycogen Storage Disease Type II
Itepekimab SAR440340	Phase 3	Chronic Obstructive Pulmonary Disease
Insulin glulisine QD	Phase 3	Type 2 Diabetes
G-CSF Plus Plerixafor	Phase 2	Lymphoma, Non-Hodgkin
frexalimab	Phase 2	Focal Segmental Glomerulosclerosis

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for SNYNF (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 20 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.